Dr. Goldstein serves as a Partner of Aisling Capital. Previously, Dr. Goldstein was Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals up until its acquisition by Pfizer for $1.9 billion. While at Vicuron Pharmaceuticals, he raised over $250 million dollars in an IPO, PIPE, Follow-on, and block trade transactions. He led the valuation and finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI), the first US and Italian public to public company merger. He also ran the investor relations and press relations efforts for the company. Prior to Vicuron, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures. He also completed an internship in the Department of Medicine, at Columbia-Presbyterian Hospital.

Dr. Goldstein currently serves as a director of ADMA Biologics, Inc., BioRelix, Inc., CardioKine, Inc., Cempra Pharmaceuticals, Inc., Esperion Therapeutics, Inc.  and Topaz Pharmaceuticals, Inc.

Dr. Goldstein received his M.D. from Yale School of Medicine. He received his M.B.A. from Columbia Business School and his B.S. with honors from Stanford University.

Dennis Purcell
Steven A. Elms
Andrew Schiff
Dov A. Goldstein
Anthony Y. Sun
Brett I.W. Zbar
Josh Bilenker
Aftab R. Kherani
Stacey D. Seltzer
Christine Lee Ha
Justin Sun
Jacob Van Naarden
Lloyd E. Appel
Andrew P. Nicholson
Robert J. Wenzel
Diana Robinson
Jan Hoerrner